抗HIV治療ガイドライン（2021年3月発行）

ガイドラインを検索

IX抗HIV薬の副作用

文献

  1. Keiser O, Fellay J, Opravil M, et al. Adverse events to antiretrovirals in the Swiss HIV Cohort Study. Antivir Ther. 12(8):1157-64. 2007.
  2. Orkin C, Squire KE, Molina JM, et al. Doravirine/Lamivudine/Tenofovor Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naïve Adults With Human Immunodeficiency Virus-I Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2019; 68(4):535-544.
  3. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 372:646-55, 2008.
  4. Smith KY, Weinberg WG, Dejesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabone, for the initial treatment of HIV infection. AIDS Res Ther. 5:5, 2008.
  5. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naïve, HIV-1- infected patients: 96-week analysis. AIDS. 23:1679-88, 2009.
  6. Maggi P, Di Biagio A, Rusconi S, et al. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis.17(1):551. 2017.
  7. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naïve Patients. JAMA, 292:191-201, 2004.
  8. Moyle GJ, Stellbrink HJ, Compston J, et al. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther. 18:905-13, 2013.
  9. Glidden DV, Mulligan K, McMahan V, et al. Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine. Clin Infect Dis. 2018 Jul 18;67(3):411-419.
  10. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 352:48-62, 2005.
  11. O’Halloran J, Sahrmann J, Olsen M, et al. Incident diabetes associated with integrase strand transfer inhibitor initiation. Presented at: virtual Conference on Retroviruses and Opportunistic Infections; 2021 Absr 516.
  12. Van Wyk、Ait-Khald M, Santos J, et al. Improved metabolic parameters after switching from TAF-based 3-0r 4-drug regimen to the 2-drug regimen of DTG/3TC (dolutegravir/lamivudine): the TANGO study. 23rd International AIDS Conference 2020 Absr OAB0606.
  13. Friis-Møller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 349:1993-2003, 2003.
  14. d'Arminio A, Sabin CA, Phillips AN, et al. Cardio- and cerebrovascular events in HIV-infected persons. AIDS. 18:1811-17, 2004.
  15. DAD Study Group, Friis-Møller N, Reiss P, Sabin CA, et al. Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. N Engl J Med. 356:1723-35, 2007.
  16. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 201(3):318-30. 2010
  17. Ryom L,Lundgren JD, El-Sadr WM,et al.Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV. 5(6):e291-e300. 2018
  18. D:A:D Study Group, Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: amulticohort collaboration. Lancet. 371:1417-26, 2008.
  19. Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 22:F17-F24, 2008.
  20. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr, 51:20-28, 2009.
  21. Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr. 61:441-47, 2012.
  22. D:A:D Study Group, Friis-Møller N, Ryom R, Smith C, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Cardiol 23: 214-23, 2016.
  23. Isezuo SA, Makusidi MA. Metabolic dysfunctions in non-antiretroviral treated HIV/AIDS patients. Niger J Clin Pract. 12:375- 78, 2009.
  24. Ehrenreich H, Rieckmann P, Sinowatz F, et al. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol. 150:4601-9, 1993.
  25. Gutierrez J, Albuquerque ALA, Falzon L. HIV infection as vascular risk: A systematic review of the literature and meta-analysis. PLoS One.12(5):e0176686. 2017.
  26. Maggi P, Di Biagio A, Rusconi S, et al. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis.17(1):551. 2017.
  27. Aberg JA, Gallant JE, Ghanem KG, et al; Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis. 58(1):1-10. 2014.
  28. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr. 35:538-9, 2004.
  29. DHHS: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV (Feb. 24, 2021). https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines
  30. Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis. 49:626-35, 2009.
  31. Hamada Y, Nishijima T, Watanabe K, et al. High Incidence of Renal Stones Among HIV-Infected Patients on Ritonavir-Boosted Atazanavir Than in Those Receiving Other Protease Inhibitor-Containing Antiretroviral Therapy. Clin Infect Dis. 55(9):1262-9, 2012.
  32. Nishijima T, Hamada Y, Watanabe K, et al. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients. PLoS One, 8:e77268, 2013.
  33. Rule AD, Bergstralh EJ, Melton LJ 3rd, et al. Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol, 4:804-11, 2009.
  34. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIVpositive patients. AIDS. 24:1667-78, 2010.
  35. Young J, Schäfer J, Fux CA, et al. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS, 26:567-75, 2012.
  36. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 21:1273-81, 2007.
  37. Nishijima T, Komatsu H, Gatanaga H, et al. Impact of small body weight on tenofovir-associated renal dysfunction in HIVinfected patients: a retrospective cohort study of Japanese patients. PLoS One. 6:e22661, 2011.
  38. Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS. 23:1971-75, 2009.
  39. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse- transcriptase inhibitor-based therapy. J Infect Dis. 197:102-8, 2008.
  40. Nishijima T, Shimbo T, Komatsu H, et al. Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study. J Infect Chemother, 19:850-7, 2013.
  41. Gatanaga H, Nishijima T, Tsukada K, et al. Clinical importance of hyperbeta-2-microglobulinuria in patients with HIV-1 infection on tenofovir-containing antiretroviral therapy. J Acquir Immune Defic Syndr. 65:e155-7, 2014.
  42. Ruane PJ, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr.63(4):449-55.2013.
  43. Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis.16(1):43-52. 2016.
  44. Raffi F, Orkin C, Clarke A, et al. Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults. J Acquir Immune Defic Syndr.75(2):226-31. 2017.
  45. Post FA, Tebas P, Clarke A, et al. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr.74(2):180-4. 2017.
  46. Wohl D, Oka S, Clumeck N, et al. A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. J Acquir Immune Defic Syndr.72(1):58-64. 2016.
  47. Arribas JR, Thompson M, Sax PE, et al. Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results. J Acquir Immune Defic Syndr.75(2):211-218. 2017.
  48. Yanagisawa N, Ando M, Ajisawa A, et al. Clinical Characteristics of Kidney Disease in Japanese HIV-Infected Patients. Nephron Clin Pract. 118:c285-c291, 2011.
  49. 村松　崇, 柳澤如樹, 近澤悠志, 他.本邦のHIV感染者における慢性腎臓病の有病率　2施設での調査結果.感染症学雑誌 87：14-21, 2013
  50. Fernando SK, Finkelstein FO, Moore BA, et al. Prevalence of chronic kidney disease in an urban HIV infected population. Am J Med Sci. 335:89-94, 2008.
  51. Mocroft A, Kirk O, Gatell J, et al. Chronic renal failure among HIV-1-infected patients. AIDS. 21:1119-27, 2007.
  52. Nishijima T, Kawasaki Y, Tanaka N, et al. Long-term exposure to tenofovir continuously decrease renal function in HIV-1- infected patients with low body weight: results from 10 years of follow-up. AIDS, 28:1903-10, 2014.
  53. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr. 61(1):32-40, 2012.
  54. Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol, 75:990-6, 2013.
  55. Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study. J Infect Dis. 210(3):354-62. 2014.
  56. 宮崎有紀，楠木靖史，小島裕人，他. 日本人を含む世界のHLA-B*57:01分布について─アバカビル過敏症に対する考察 ─日本エイズ学会誌19 : 24-28, 2017.
  57. Honda H, Tsukada K, Yazaki H, et al. Low incidence of abacavir-associated hypersensitivity reactions in Japanese HIV-1- infected patients. 4th IAS Conference 2007, Sydney, MOPEB005
  58. Brown TT, Qaquish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 20:2165-74, 2006.
  59. Cazanave C, Dupon M, Lavignolle-Aurillac V, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 22:395-402, 2008.
  60. Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acuir Immune Defic Syndr. 51:554-61, 2009.
  61. Grund B, Peng G, Gibert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS. 23:1519-29, 2009.
  62. Fux CA, Rauch A, Simcock M, et al. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther. 13:1077-82, 2008.
  63. Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses. 25:387-94, 2009.
  64. Borderi M, Gibellini D, Vescini F, et al. Metabolic bone disease in HIV infection. AIDS. 23:1297-1310, 2009.
  65. European AIDS Clinical Society (EACS) Guidelines. Version10.1 – October, 2020. http://www.europeanaidsclinicalsociety.org/よりダウンロード可能
  66. Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med, 161:1-10, 2014.
  67. Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis. 45:1230-7, 2007.
  68. de Boer MG, van den Berk GE, van Holten N, et al. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS. 30(18):2831-4. 2016.
  69. Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 18(1):56-63. 2017.
  70. Yagura H, Watanabe D, Nakauchi T, et al. EFFECT OF DOLUTEGRAVIR PLASMA CONCENTRATION ON CENTRAL NERVOUS SYSTEM SIDE EFFECTS. CROI2017 Abstract 426.
  71. Yagura H, Watanabe D, Kushida H, et al. Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. BMC Infect Dis.17(1):622. 2017.
  72. McComsey G. and Lonergan JT. Mitochondrial Dysfunction: Patient Monitoring and Toxicity Management. J Acquir Immune Defic Syndr. 37:S30-S35, 2004.
  73. John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS. 15:717-23, 2001.
  74. A Arenas-Pinto, AD Grant, S Edwards, et al. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect. 79:340-3, 2003.
  75. HIV Neuromuscular Syndrome Study Group. HIV-associated neuromuscular weakness syndrome. AIDS. 18:1403-12, 2004.
  76. Schambelan M, Benson CA, Carr A, et al; International AIDS Society-USA. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr. 31:257-75, 2002.
  77. Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia and insulin resistance. Lancet. 351:1881-3, 1998.
  78. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 351:871- 5, 1998.
  79. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 38: 263-70, 2004.
  80. McComsey GA, Kitch D, Sax PE, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis. 53(2):185-96. 2011.
  81. Sax PE, Erlandson KM, Lake JE et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020; 71(6):1379-1389.
  82. Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019; 381(9):803-815.
  83. Bourgi K, Rebeiro PF, Turner M et al. Greater weight gain in treatment naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2020; 70(7):1267-1274.
  84. Bourgi K, Jenkins C, Rebeiro PF, et al. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc. 2020 Apr;23(4):e25484.
  85. Bedimo R, Li X, Adam-Huet B, et al. Different BMI changes following PI-and InSTI-based ART initiation by sex and race. Presented at: Conference on Retroviruses and Opportunistic Infections; 2019; Seattle, WA.
  86. Venter WDF, Sokhela S, Simmons B, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020 Oct;7(10):e666-e676.
  87. McComsey GA, Sax P, Althoff KN, et al. Weight gain after switching different integrase strand transfer inhibitors(InSTIs). Presented at: virtual Conference on Retroviruses and Opportunistic Infections; 2021 Absr 503.
  88. Gomez M, Seybold U, Roider J, et al. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017. Infection. 2019; 47(1): 95-102.
  89. Mallon. 23rd International AIDS Conference 2020 Abstr OAB0604.
  90. Palella F, Hou Q, Li J, et al. Weight gain among PWH who switch to ART-containing InSTIs or TAF. Presented at: virtual Conference on Retroviruses and Opportunistic Infections; 2021 Absr 504.
  91. Hare CB, Coll J, Ruane P, et al. The phase 3 DISCOVER study: daily F/TAF or F/TDF for HIV preexposure prophylaxis. Lancet 2020; 396:236-54.
  92. Orkin C, Elion R, Thompson M, et al. Changes in weight and BMI with first-line doravirine-based therapy. AIDS. 2021 Jan 1;35(1):91-99.
  93. Bedimo R, Adams-Huet B, Taylor BS, et al. Integrase inhibitor-based HAART is associated with greater BMI gains in blacks, Hispanics and women. Presented at: IDWeek; 2018; San Fransisco, CA.
  94. HIV感染症治療薬共同使用成績調査　2020報告書、シミックPMS社 https://www.hrd.gr.jp/common/kyoudou/index.html からダウンロード可能.
  95. Hill A, Mac Cann KM, Polkington V, et al. Risk of metabolic syndrome, diabetes, and cardiovascular disease in Advance trial. Presented at: Conference on Retroviruses and Opportunistic Infections; 2020; Boston, abstract 81.
  96. Petoumenos K, Kuwanda L, Ryom L, et al. Effect of changes in body mass index on the risk of cardiovascular disease and diabetes mellitus in HIV-positive individuals: results from the D: A: D study. J Acquir Immune Defic Syndr. 2020 Dec 17.
  97. Kikuchi Y, Genka I, Ishizaki A. et al. Serious Bradyarrhythmia That Was Possibly Induced by Lopinavir-Ritonavir in 2 Patients with Acquired Immunodeficiency Syndrome. Clin Infect Dis. 35(4), 488-90, 2002.
  98. Zembower TR, Gerzenshtein L, Coleman K, et al. Severe rhabdomyolysis associated with raltegravir use. AIDS. 22(11):1382-4, 2008.
  99. Madeddu G, De Socio GV, Ricci E, et al. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance. Int J Antimicrob Agents. 45(3):289-94, 2015.
  100. Rakotondravelo S, Poinsignon Y, Borsa-Lebas F, et al. Complicated atazanavir-associated cholelithiasis: a report of 14cases. Clin Infect Dis. 55(9):1270-2, 2012.
  101. Nishijima T, Shimbo T, Komatsu H, et al. Cumulative exposure to ritonavir-boosted atazanavir is associated with cholelithiasis in patients with HIV-1 infection. J Antimicrob Chemother. 69(5):1385-9, 2014.
  102. Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med.379(10):979-81. 2018.
  103. Zash R, Holmes L, Diseko M, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med. 2019;381(9):827-840.
  104. Raesima MM, Ogbuabo CM, Thomas V, et al. Dolutegravir use at conception - additional surveillance data from Botswana. N Engl J Med. 2019;381(9):885-887.
  105. Zash R, Holmes L, Diseko M, et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. 23rd International AIDS Conference 2020. #OAXLB0102.
  106. Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States. (米国DHHS、Feb. 10, 2021). https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new-guidelines

PAGE TOP

前のページへ
次のページへ

アンケートにご協力ください。

このページは役に立ちましたか？

コメント